The patent is a modest positive for PrimeC's commercial prospects, but the company's survival depends on securing financing. Monitor for partnership or funding announcements to address the going concern risk.
Price Chart
Executive Summary
NeuroSense Therapeutics announced it was granted a South Korean patent covering its lead ALS drug PrimeC, providing protection through 2042. While this adds to the company's growing global IP portfolio, it does not alleviate the severe cash crunch ($0.2M cash) identified in the prior annual report.
Key Facts
- Korean Intellectual Property Office issued patent covering PrimeC composition, formulation, manufacturing, and ALS use through 2042.
- Patent follows grants in Japan, Brazil, Australia, and the United States.
- Company preparing for Phase 3 PARAGON study but had only $0.2M cash as of last annual report (20-F, March 2026).
Financial Impact
No immediate revenue or cash impact; patent strengthens long-term commercialization potential but does not address near-term funding needs.
Risk Factors
- Cash position of $0.2M raises substantial doubt about ability to continue as a going concern.
- PrimeC is still in development; Phase 3 results are uncertain.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-067577 |
| Document: ea0294275-6k_neurosense.htm | 0001213900-26-067577 |
| Document: 0001213900-26-067577-index-headers.html | 0001213900-26-067577 |
| Document: 0001213900-26-067577-index.html | 0001213900-26-067577 |
| Document: 0001213900-26-067577.txt | 0001213900-26-067577 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | 6-K | $2.67 $2.39 | ▼ −10.32% | ▼ −10.65% | $2.46 (−7.69%) |
Oct 13, 2026 13d ago | 6-K | $3.49 $3.06 | ▼ −12.32% | ▼ −11.24% | $2.46 (−29.51%) |
Sep 25, 2026 4w ago | 6-K | $5.10 $4.78 | ▲ +6.27% | ▲ +6.09% | $2.46 (+51.76%) |
Aug 6, 2026 11w ago | 6-K | $0.5030 $0.4999 | ▼ −0.62% | ▼ −1.23% | $2.46 (+389.07%) |
Jul 22, 2026 13w ago | 6-K | $0.6500 $0.6550 | ▲ +0.77% | ▲ +2.00% | $2.46 (+278.46%) |
Jun 29, 2026 17w ago | 6-K | $0.7099 $0.7200 | ▲ +1.42% | ▲ +0.64% | $2.46 (+246.53%) |
Jun 17, 2026 18w ago | Insider Cluster | $16.10 $15.78 | ▼ −1.99% | ▼ −1.67% | $2.46 (−84.72%) |
Jun 11, 2026 19w ago | 6-K | $0.7390 $0.7352 | ▼ −0.51% | ▼ −1.05% | $2.46 (+232.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers